Rodríguez-Carballo Edgardo, Gámez Beatriz, Méndez-Lucas Andrés, Sánchez-Freutrie Manuela, Zorzano Antonio, Bartrons Ramon, Alcántara Soledad, Perales José Carlos, Ventura Francesc
*Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.
*Departamente de Ciències Fisiològiques II and and Departament de Patologia i Terapèutica Experimental, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain; Institute for Research in Biomedicine, Barcelona, Spain; and Centro de Investigación Biomédica en Red (CIBER) de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain
FASEB J. 2015 Apr;29(4):1414-25. doi: 10.1096/fj.14-261891. Epub 2014 Dec 30.
The skeleton acts as an endocrine organ that regulates energy metabolism and calcium and phosphorous homeostasis through the secretion of osteocalcin (Oc) and fibroblast growth factor 23 (FGF23). However, evidence suggests that osteoblasts secrete additional unknown factors that contribute to the endocrine function of bone. To search for these additional factors, we generated mice with a conditional osteoblast-specific deletion of p38α MAPK known to display profound defects in bone homeostasis. Herein, we show that impaired osteoblast function is associated with a strong decrease in body weight and adiposity (P < 0.01). The differences in adiposity were not associated with diminished caloric intake, but rather reflected 20% increased energy expenditure and the up-regulation of uncoupling protein-1 (Ucp1) in white adipose tissue (WAT) and brown adipose tissue (BAT) (P < 0.05). These alterations in lipid metabolism and energy expenditure were correlated with a decrease in the blood levels of neuropeptide Y (NPY) (40% lower) rather than changes in the serum levels of insulin, Oc, or FGF23. Among all Npy-expressing tissues, only bone and primary osteoblasts showed a decline in Npy expression (P < 0.01). Moreover, the intraperitoneal administration of recombinant NPY partially restored the WAT weight and adipocyte size of p38α-deficient mice (P < 0.05). Altogether, these results further suggest that, in addition to Oc, other bone-derived signals affect WAT and energy expenditure contributing to the regulation of energy metabolism.
骨骼作为一个内分泌器官,通过分泌骨钙素(Oc)和成纤维细胞生长因子23(FGF23)来调节能量代谢以及钙和磷的体内平衡。然而,有证据表明成骨细胞会分泌其他未知因子,这些因子有助于骨骼的内分泌功能。为了寻找这些额外的因子,我们构建了条件性成骨细胞特异性缺失p38α丝裂原活化蛋白激酶(MAPK)的小鼠,已知该蛋白在骨稳态中表现出严重缺陷。在此,我们表明成骨细胞功能受损与体重和肥胖的显著下降有关(P < 0.01)。肥胖的差异与热量摄入减少无关,而是反映出能量消耗增加了20%,以及白色脂肪组织(WAT)和棕色脂肪组织(BAT)中解偶联蛋白-1(Ucp1)的上调(P < 0.05)。脂质代谢和能量消耗的这些改变与神经肽Y(NPY)血液水平的降低(降低40%)相关,而不是与胰岛素、Oc或FGF23血清水平的变化相关。在所有表达Npy的组织中,只有骨骼和原代成骨细胞显示Npy表达下降(P < 0.01)。此外,腹腔注射重组NPY部分恢复了p38α缺陷小鼠的WAT重量和脂肪细胞大小(P < 0.05)。总之,这些结果进一步表明,除了Oc之外,其他源自骨骼的信号会影响WAT和能量消耗,从而有助于能量代谢的调节。